Payment overview · 2025
General Payments
$364.64
12 reported records · 5 companies
Healthcare provider profile · identity verified
John Calvin Both, D.O.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · MAUMEE, OH · NPI 1760489322
Verified facts
What the public records show
CMS Open Payments records show John Calvin Both, D.O. received $364.64 in general payments during 2025 across 12 reported records.
Boston Scientific Corporation accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $137.84 | 37.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.17 | 37.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.92 | 10.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.22 | 9.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.49 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $364.64 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $137.84 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $120.17 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $41.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 111 |
| Eliquis | Apixaban | 405 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 79 |
| Lisinopril | Lisinopril | 321 | 82 |
| Potassium Chloride | Potassium Chloride | 308 | 55 |
| Gabapentin | Gabapentin | 289 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 67 |
| Losartan Potassium | Losartan Potassium | 265 | 62 |
| Omeprazole | Omeprazole | 237 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 44 |
| Metformin Hcl | Metformin Hcl | 227 | 63 |
| Sertraline Hcl | Sertraline Hcl | 226 | 47 |
| Donepezil Hcl | Donepezil Hcl | 216 | 38 |
| Famotidine | Famotidine | 201 | 42 |
| Furosemide | Furosemide | 201 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 45 |
| Buspirone Hcl | Buspirone Hcl | 195 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 40 |
| Trazodone Hcl | Trazodone Hcl | 175 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 33 |
| Simvastatin | Simvastatin | 156 | 30 |
| Allopurinol | Allopurinol | 135 | 25 |
| Januvia | Sitagliptin Phosphate | 129 | 16 |
| Mirtazapine | Mirtazapine | 123 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 24 |
| Memantine Hcl | Memantine Hcl | 117 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 25 |
| Carvedilol | Carvedilol | 104 | 27 |
| Levetiracetam | Levetiracetam | 98 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 86 | 12 |
| Celecoxib | Celecoxib | 86 | 12 |
| Alendronate Sodium | Alendronate Sodium | 85 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 17 |
| Myrbetriq | Mirabegron | 75 | suppressed |
| Bumetanide | Bumetanide | 72 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 17 |
| Prednisone | Prednisone | 72 | 32 |
| Montelukast Sodium | Montelukast Sodium | 69 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 16 |
| Alprazolam | Alprazolam | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Warfarin Sodium | Warfarin Sodium | 68 | 11 |
| Divalproex Sodium | Divalproex Sodium | 67 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 11 |
| Tramadol Hcl | Tramadol Hcl | 65 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 14 |
| Baclofen | Baclofen | 62 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 14 |
| Novolog Flexpen | Insulin Aspart | 60 | 12 |
| Atenolol | Atenolol | 58 | 13 |
| Finasteride | Finasteride | 56 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Risperidone | Risperidone | 56 | 11 |
| Sucralfate | Sucralfate | 56 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Primidone | Primidone | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Jardiance | Empagliflozin | 54 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Meloxicam | Meloxicam | 53 | 18 |
| Meclizine Hcl | Meclizine Hcl | 52 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | suppressed |
| Amoxicillin | Amoxicillin | 51 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 22 |
| Spironolactone | Spironolactone | 51 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 20 |
| Midodrine Hcl | Midodrine Hcl | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 11 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 23 |
| Nystatin | Nystatin | 36 | 18 |
| Budesonide | Budesonide | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 21 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Cilostazol | Cilostazol | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Lacosamide | Lacosamide | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Oxaprozin | Oxaprozin | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $364.64 · 12 records | Boston Scientific Corporation | AIRSUPRA, CREON, Cologuard Collection Kit, FARXIGA, LINZESS, REXULTI, WATCHMAN Access System | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error